Work

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Year: 2007

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v110.11.4504.4504

Authors: Razelle Kurzrock, Paul Hamlin, Anas Younes, David Hong, Michael Gordon, Matthew A. Spear, Michael A. Palladino, G. Kenneth Lloyd, Angie M. Longenecker, Saskia T.C. Neuteboom, Gillian F. Cropp, Alison Hannah, Carol Aghajanian

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Pinnacle Oncology Hematology

Language: English

Topic: Ubiquitin and proteasome pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2551142268

FWCI: 0.24

Cites:

Cited by: 6

Related to: 10